Ikarian Capital’s Milestone Pharmaceuticals MIST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-466,030
Closed -$1.1M 195
2024
Q4
$1.1M Buy
466,030
+11
+0% +$19 0.15% 105
2024
Q3
$708K Hold
466,019
0.1% 111
2024
Q2
$620K Hold
466,019
0.11% 88
2024
Q1
$834K Buy
466,019
+3,191
+0.7% +$5.18K 0.09% 108
2023
Q4
$773K Hold
462,828
0.07% 106
2023
Q3
$1.43M Buy
462,828
+2,412
+0.5% +$7.5K 0.17% 88
2023
Q2
$1.31M Hold
460,416
0.21% 79
2023
Q1
$1.81M Hold
460,416
0.41% 60
2022
Q4
$1.82M Sell
460,416
-395,200
-46% -$2.08M 0.44% 43
2022
Q3
$7.86M Sell
855,616
-523,806
-38% -$3.97M 1.57% 20
2022
Q2
$8.19M Sell
1,379,422
-549,330
-28% -$3.38M 1.49% 23
2022
Q1
$12.4M Buy
1,928,752
+178,709
+10% +$1.12M 1.63% 15
2021
Q4
$11.5M Hold
1,750,043
1.71% 15
2021
Q3
$9.99M Sell
1,750,043
-230,357
-12% -$1.3M 0.7% 39
2021
Q2
$10.9M Buy
1,980,400
+143,855
+8% +$816K 0.88% 31
2021
Q1
$10.6M Hold
1,836,545
0.36% 62
2020
Q4
$12.3M Buy
1,836,545
+93,000
+5% +$623K 0.54% 43
2020
Q3
$12.8M Buy
+1,743,545
New +$12.5M 0.92% 28

Other funds holding MIST

Ikarian Capital's MIST Position: Q1 2025 in Review

Ikarian Capital sold out of Milestone Pharmaceuticals (MIST) in Q1 2025, closing a stake of 466,030 shares — an estimated $1.1M sold.

Ikarian Capital first reported a position in MIST in Q3 2020 and held it in 18 quarters. The position peaked at $12.8M in Q3 2020. 43 funds tracked by Wall St. Rank hold MIST as of Q1 2025.

  • Ikarian Capital reported no remaining Milestone Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Ikarian Capital sold 466,030 Milestone Pharmaceuticals shares in Q1 2025, an estimated $1.1M.
  • Ikarian Capital first reported a position in Milestone Pharmaceuticals in Q3 2020 and held it in 18 quarters.
  • Ikarian Capital's Milestone Pharmaceuticals position peaked at $12.8M in Q3 2020.
  • 43 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q1 2025.

Based on Ikarian Capital's 13F filing for Q1 2025, filed 15 May 2025.